NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice

Cited by (148)

Items 101–148 of 148

1. Toll-like receptor 4 signaling pathway mediates both liver and kidney injuries in mice with hepatorenal syndrome
   Mingliang Wang, Tingting Qin, Yunyun Zhang, Ting Zhang, Zirui Zhuang, Yingyu Wang, Yongfang Ding, Yunru Peng · 2022 · American Journal of Physiology-Gastrointestinal and Liver Physiology
2. Neutrophil extracellular traps mediate pathophysiology of hepatic cells during liver injury
   Ki Mark Mak, Aditya C. Shekhar, Selena Y. Ding · 2025 · The Anatomical Record
3. CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway
   Shaopeng Zhang, Xinzheng Dai, Yong Shi, Xiaowen Zhu, Yongjiu Dai, Xiaofeng Qian, Jian Hong Gu · 2021 · Annals of Translational Medicine
4. Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz
   Fernando Alegre, Alberto Martí-Rodrigo, Miriam Polo, D Ortiz‐Masiá, Celia Bañuls, Marcello Pinti, Ángeles Álvarez, Nadezda Apostolova, Juan Vicente Esplugues, Ana Blas‐García · 2022 · Biomedicines
5. Use of wogonin as a cooperative drug with praziquantel to better combat schistosomiasis
   Ho Yin Pekkle Lam, Meng-Yun Hung, Po-Ching Cheng, Shih-Yi Peng · 2022 · Journal of Microbiology Immunology and Infection
6. Role of NLRP3 in the metabolism of bile acids and gut microbiota in CCl4-induced liver fibrosis
   Shu Ying Feng, Ran Tao, Xingming Xie, Xueke Zhao · 2025 · Microbiology Spectrum
7. Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease
   Marcos F. Fondevila, Henriette Kreimeyer, Cynthia L. Hsu, Joaquin Tamargo‐Azpilicueta, Le Z. Day, Marina Gritsenko, Kwame Attah, Noemí Cabré, Aenne Harberts, Fernanda Raya Tonetti et al. · 2026 · Journal of Hepatology
8. The anti-liver fibrosis effect of Tibetan medicine (Qiwei Tiexie capsule) is related to the inhibition of NLRP3 inflammasome activation in vivo and in vitro
   Shanshan Wang, Fei Ye, Qingjia Ren, Shengnan Sun, Weina Xia, Zhuwei Wang, Haolin Guo, Han Li, Shujing Zhang, Scott Lowe et al. · 2023 · Journal of Ethnopharmacology
9. Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis
   Meihua Sun, Yanqing Zhang, Anbing Guo, Zongting Xia, Lijun Peng · 2023 · Journal of Clinical and Translational Hepatology
10. Obeticholic acid attenuates human immunodeficiency virus/alcohol metabolism-induced pro-fibrotic activation in liver cells
    Moses New‐Aaron, Murali Ganesan, Raghubendra Singh Dagur, Kusum K. Kharbanda, Larisa Y Poluektova, Natalia A. Osna · 2020 · World Journal of Hepatology
11. Pyroptosis is involved in maternal nicotine exposure‐induced metabolic associated fatty liver disease progression in offspring mice
    Yu‐Qing Su, Yan Heather Lin, Shu‐Jing Huang, Yan‐Ting Lin, Jing Ran, Fang‐Fang Yan, Xian‐Lan Liu, Long‐Cheng Hong, Mei Huang, Huan‐Zhong Su et al. · 2023 · Molecular Reproduction and Development
12. Chronological activation of the NLRP3 inflammasome/pyroptosis pathway in the progression from metabolic dysfunction-associated fatty liver disease to hepatocellular carcinoma
    Linda Vanessa Márquez-Quiroga, Eduardo E. Vargas-Pozada, Irina Cardoso-Lezama, Erika Ramos‐Tovar, Verónica Rocío Vásquez-Garzón, Carolina Piña‐Vázquez, Saúl Villa‐Treviño, Jaime Arellanes‐Robledo, Pablo Muriel · 2025 · Toxicology Mechanisms and Methods
13. Zexie-Baizhu herb pair attenuates MASH via the gut-liver Axis by suppressing NLRP3 Inflammasome activation and M1-macrophage polarization
    Chengqi Ma, Yun Liu, Tangqing Zeng, Xiang Li, Xinyue Tan, Xiaoqiang Ma, Xu Lu, Yirui Wang, Xiaoyu Wu · 2025 · Bioorganic Chemistry
14. Hepatic SPARC Expression Is Associated with Inflammasome Activation during the Progression of Non-Alcoholic Fatty Liver Disease in Both Mice and Morbidly Obese Patients
    Agostina M. Onorato, Lucía Lameroli Mauriz, Juan Bayo, Esteban Juan Fiore, María José Cantero, Bárbara Bueloni, Mariana Gabriela García, Cecilia Lagües, Pedro Martinez‐Duartez, Gabriel Menaldi et al. · 2023 · International Journal of Molecular Sciences
15. NLRP3 inflammasome activation promotes liver inflammation and fibrosis in experimental biliary atresia
    Junfeng Wang, Min Du, Lingdu Meng, Shiwei He, Ye Zhu, Yifan Yang, Xue Ren, Yanlei Huang, Song Sun, Rui Dong et al. · 2023 · Digestive and Liver Disease
16. Lysosomal hydrolases, from waste-bags effectors to essential multipurpose enzymes in liver fibrosis
    María Fernández-Fernández, Paloma Ruiz-Blázquez, Júlia Cacho-Pujol, Anna Moles · 2023 · Exploration of Digestive Diseases
17. Auranofin attenuates Schistosoma mansoni egg-induced liver granuloma and fibrosis in mice
    Amany Fawzy Atia, NOHA M. ABOU HUSSIEN, Dina Sweed, Eman M. Sweed, Noha Abokhalil · 2023 · Journal of Helminthology
18. The Pathophysiology of Hepatic Encephalopathy at the Level of Gut-Liver-Brain Axis: The Role of Resident Innate Immune Cells
    Ali Sepehrinezhad, Ali Shahbazi · 2024 · IntechOpen eBooks
19. Network pharmacology and transcriptomic profiling elucidate the therapeutic effects of Ranunculus ternatus Thunb on liver fibrosis via MK3-NF-κB inhibition
    Lu Han, Guoyuan Lin, Jianchao Li, Qingxiu C. Zhang, Ran Tao, Tao Huang, Rui-Han Hu, Shu Feng, Gao-Liang Zou, Shaojie Chen et al. · 2024 · Aging
20. CD44-Targeted pH-Responsive Nanoenzyme-Liposome Complexes Co-Delivering Ceria Nanozymes and Cryptotanshinone To Alleviate Liver Fibrosis.
    Kai Liu, Yu-Xin Zhao, Nini Luo, Jia Luo, Xiao-Fang Li · 2026 · Molecular Pharmaceutics
21. Synthesis and pharmacological evaluation of brominated derivatives of natural product celastrol for treatment of hepatic fibrosis
    Meng-Yu Li, Yang Li, Xiaomin Wang, Fan-Fan Shang, Yuting Long, Yong-Ling Li, Zhengyuan Wang, Ao Zhang, Hao Zhang, Chunyong Ding et al. · 2026 · European Journal of Medicinal Chemistry
22. Co-exposure to different bacterial species’ lipopolysaccharides with the NASH diet exacerbates NASH and liver fibrosis progression in mice
    Yen-Peng Lee, Chien-Chao Chiu, Yung‐Chi Chang, Yi‐Hsun Chen, Wei‐Kai Wu, Ming‐Shiang Wu, Hsiao-Li Chuang · 2024 · Clinics and Research in Hepatology and Gastroenterology
23. Inflammasome-induced inflammation and fibrosis in liver
    Benedikt K. Kaufmann, Andrea D. Kim, Ariel E. Feldstein · 2022 · Elsevier eBooks
24. Curcumin as a modulator of IL-18: A promising therapeutic approach for inflammatory diseases
    Maryam Kavyani, Sahar Ghoflchi, Saba Miri Disfani, Mohammad Jalili‐Nik, Asie Sadeghi, Sercan Karav, Prashant Kesharwani, Hossein Hosseini, Amirhossein Sahebkar · 2025 · Food Bioscience
25. Fucoidan ameliorates alcoholic liver fibrosis through modulation of the gut-bile acid-liver metabolic axis
    Yexin Pu, Zijian Zhou, Haoran Xue, Yanxia Ma, Nan Zhang, Guifa Wang, Shuo Zang, Ziwei Liu, Meilan Xue, Hui Liang · 2026 · Food Bioscience
26. Quercetin Attenuates Non-Alcoholic Fatty Liver Disease in Association with the Inhibition of Hepatic IL-1β/iNOS and IL-1β/CD45 Axes of Inflammation and Fibrosis Accompanied by Reduced Endogenous Metabolites and Apoptosis
    Saif Aboud Alqahtani, Alshehri Hanan Hassan, Hend Ashour, Hend A. Abdallah, Laila Rashed, Rehab Mustafa Badi, Muataz Elsiddig Dafaalla Mohammed, Bahjat Al‐Ani, Norah Mohammed AlZamil, Alia Saeed Albawardi et al. · 2026 · Metabolites
27. Emerging biomodels to understand the pathophysiology of sepsis and evaluate new therapeutic strategies targeting extracellular histones
    Jose Luis García‐Giménez, Marta Seco-Cervera, Irene Cánovas‐Cervera, Ana Belén Agúndez, Enric Dolz-Andrés, Gonzalo Mondaray-Muñoz, Rosa Calpe-Fortea, Elena Nácher-Sendra, Rebeca Osca-Verdegal, José Luis Aparicio-Collado et al. · 2026 · Materials Today Bio
28. Unveiling the role of aldosterone in metabolic dysfunction–associated steatotic liver disease
    Anna Hernández‐Rubio, María Teresa Julián, Elena Valassi, Núria Alonso, Manel Puig‐Domingo · 2026 · Reviews in Endocrine and Metabolic Disorders
29. [Adeno-associated virus-mediated hepatocyte-specific NDUFA13 overexpression protects against CCl4-induced liver fibrosis in mice by inhibiting hepatic NLRP3 activation].
    Xiaohui Xu, Jinmei Feng, Yan Luo, Xiaodong He, J Zang, Daochao Huang · 2024 · PubMed
30. METTL3 facilitates hepatic fibrosis progression via m 6 A-YTHDF2 dependent silencing of GPR161
    Xue‐Yin Pan, Yihui Bi, Miao Cheng, Zhenzhen Qian, Ling Wang, Hongmei You, Lei Liu, Zhenhua Zhang, Xiao‐Ming Meng, Cheng Huang et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
31. Mechanisms of Fibrogenesis in NASH
    Mirella Pastore, Alessandra Gentilini, Fabio Marra · 2020 · Springer eBooks
32. Tissue Remodeling in Health and Disease Caused by Bacteria, Parasites, Fungi, and Viruses
    2021 · Frontiers research topics
33. Activation of primary hepatic stellate cells and liver fibrosis induced by targeting TGF-β1/Smads signaling in Schistosomiasis of mice
    Ping Huang, Huihui Ma, Yun Cao, Tingzheng Zhan, Tingting Zhang, Xinyi Wang, Yanan Zhang, Jing Xu, Chao-Ming Xia · 2022 · Research Square
34. The infiltration of monocytes aggravates liver fibrosis in mice infected with Echinococcus granulosus
    Yi Yan, Fengming Tian, Xinwei Qi, Yumei Liu, Xiumin Ma, Bin Li, Jie Lv, Xuan Zhou, Xue Zhang, Yuyu Ma · 2022 · Research Square
35. Mincle-GSDMD-mediated release of IL-1β containing small extracellular vesicles contributes to ethanol-induced liver injury
    Quanri Zhang, Weiwei Liu, Katarzyna Bulek, Han Wang, Megan R. McMullen, Xiaoqin Wu, Nicole Welch, Renliang Zhang, Jaividhya Dasarathy, Srinivasan Dasarathy et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
36. Sustained drug delivery to reduce the extent of burn progression
    Moogaambikai D/O Thangaveloo · 2024
37. miRNA-29b-3p: An Important Target for Ameliorating Liver Fibrosis in Wilson Disease by Inhibiting Autophagy
    Peng Huang, Yuzhe Huang, Ting Dong, Yulong Yang, Wei He, Meixia Wang, Han Wang, Wenming Yang · 2025 · Current Molecular Medicine
38. Targeting inflammatory dysregulation in metabolic dysfunction-associated steatotic liver disease rat model: the preventive and therapeutic effects of acetyl-11-keto-beta-boswellic acid
    Sajad Ehtiati, Roya Pakrad, Seyyed Hossein Khatami, Reza Ataei Kachouei, Alireza Doagoo, Hossein Lanjanian, Seyyed Amir Hossein Ghazizadeh Hashemi, N.A. Hamed, Behzad Hatami, Reyhane Ahmadzade et al. · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
39. Unravelling the impact of NLRP3 inflammasome in fibrosis: Molecular insights into the fibrosis of diverse tissues and potential therapeutic options
    Mihir Parikh, Arun Soni, Tejal Ricky Gandhi · 2025 · Elsevier eBooks
40. OLR1 Knockdown Mitigates Traumatic-Hemorrhagic Shock-Induced Liver Injury by Inhibiting the TLR4/MYD88 Pathway and NLRP3 Inflammasome Activation
    Hongwei Yao, N. Wang, Z. Huan, Ji‐Hye Han, Mei Zhao, X. Ge · 2025 · Molecular Biology
41. Additional file 1 of Activation of primary hepatic stellate cells and liver fibrosis induced by targeting TGF-β1/Smad signaling in schistosomiasis in mice
    Huang, Ping, Ma, Huihui, Cao, Yun, Zhan, Tingzheng, Zhang, Tingting, Wang, Xinyi, Zhang, Yanan, Jing Xu, Xia, Chaoming · 2023 · Figshare
42. Additional file 1 of Exosomal miR-223 derived from natural killer cells inhibits hepatic stellate cell activation by suppressing autophagy
    Wang, Ling, Wang, Yinghao, Jun Quan · 2020 · Figshare
43. Resveratrol’s hepatic symphony: conducting a multi-stage intervention in liver cancer’s progression
    Cui Guo, Fang Cao, Ling Zhou, Guijun Guo, Shaoyuan Zheng, Ruixue Xia, Qinghua Zou · 2026 · Chinese Journal of Natural Medicines
44. Inflammasomes in digestive diseases: mechanisms and therapeutic potential
    Yanjiao Zhang, Xuefei Zhao, Zhihua Tian, M Li, Nan Luo, Xinqiao Chu, Shuxuan Chen, Tiantong Jiang, Shaoli Wang, Zhen Liu · 2026 · Molecular Biology Reports
45. Periodontitis and MASLD: a narrative review of the direct oral-hepatic pathway
    Hai He, Z Chen, Hengxiang Liu, Xiaohua Zhang, Zhiqiang Li, Tianzhu Song, Zi Wang · 2026 · Frontiers in Cellular and Infection Microbiology
46. From indirect regulation to multi-layered metabolic control in MASLD: Multi-receptor agonism and microbiota–metabolite functional convergence
    Sini Zhou, Ling Dong · 2026 · Pharmacological Research
47. MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management
    Hubert Krzewiński, Oliwier Wątroba, Jarosław Koza · 2026 · Journal of Clinical Medicine
48. Obesity-driven inflammation and immune dysregulation in cancer development and progression
    Pritika Pandey, Jeb F. Struder, Erika T. Rezeli, Evan M. Paules, Stephen David Hursting, Michael F. Coleman, Kristin Ann Altwegg · 2026 · Frontiers in Oncology